All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @drzainhasan1 on TikTok · 389s|Watch on TikTok

@drzainhasan1's tirzepatide claims, fact-checked

Dr Zain Hasan

TikTok creator

226.9K viewsWatch on TikTok →

Quick answer

Tirzepatide is a dual GLP-1/GIP receptor agonist that achieved 20.9% weight loss at the highest dose in clinical trials, outperforming semaglutide's 14.9% in separate studies. Both drugs slow gastric emptying and reduce appetite through hormone pathways, requiring gradual dose escalation over several months.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion
Start provider reviewReview Compounded Semaglutide

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @drzainhasan1's tirzepatide claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Randomized trialTirzepatide evidence2022

Tirzepatide Once Weekly for the Treatment of Obesity

Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.

PubMed

Randomized trialTirzepatide evidence2024

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction

Used for continuation, stopping, and maintenance questions after initial weight loss.

PubMed

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Start the provider review

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Helpful context before the funnel

Semaglutide video claims video hub

Compare nearby social claims before acting.

Review Compounded Semaglutide

Move from claim context to product, safety, and access details.

Review method

See how FormBlends checks viral health claims.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

View topic hubSemaglutide video claimsReview SemaglutideTreatment or product pathRead GLP-1 guideDeeper FormBlends guide

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@drzainhasan1's tirzepatide claims, fact-checked" from Dr Zain Hasan. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide is a dual GLP-1/GIP receptor agonist that achieved 20.

The reason this review is not generic is the source wording and the canonical claim label "glp1 full video save for future reference doctor tirzepatide." In this clip, the useful excerpt is: "Full video, save for future reference." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Tirzepatide targets both GLP-1 and GIP receptors while semaglutide only affects GLP-1
People who land here are usually comparing the Compounded Semaglutide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Semaglutide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tirzepatide is a dual GLP-1/GIP receptor agonist that achieved 20.

FormBlends verdict

Compounded Semaglutide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tirzepatide is a dual GLP-1/GIP receptor agonist that achieved 20.9% weight loss at the highest dose in clinical trials, outperforming semaglutide's 14.9% in separate studies. Both drugs slow gastric emptying and reduce appetite through hormone pathways, requiring gradual dose escalation over several months.
  • Tirzepatide achieved 20.9% weight loss in SURMOUNT-1 compared to semaglutide's 14.9% in STEP 1
  • Tirzepatide targets both GLP-1 and GIP receptors while semaglutide only affects GLP-1

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • Tirzepatide achieved 20.9% weight loss in SURMOUNT-1 compared to semaglutide's 14.9% in STEP 1
  • Tirzepatide targets both GLP-1 and GIP receptors while semaglutide only affects GLP-1
  • Both medications require gradual dose increases starting from low initial doses
  • Head-to-head trials show tirzepatide outperforms semaglutide 1mg in people with diabetes
  • Individual response varies significantly between the two drugs for reasons we can't predict
  • Cost and insurance coverage often differ substantially between the medications
  • Both drugs require lifestyle modifications to achieve optimal weight loss results

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this video actually claim?

Dr. Zain Hasan presents tirzepatide as superior to semaglutide for weight loss, claiming it works on both GLP-1 and GIP receptors while semaglutide only targets GLP-1. He suggests this dual action makes tirzepatide more effective for weight management and blood sugar control.

The video positions tirzepatide as the next evolution in weight loss medications. Hasan emphasizes the dual-hormone approach as a key advantage over single-receptor drugs like semaglutide.

Does the science back this up?

Yes, tirzepatide does outperform semaglutide in head-to-head studies. The SURPASS-2 trial (Frías et al., NEJM, 2021) compared tirzepatide directly to semaglutide 1mg in people with type 2 diabetes, showing superior weight loss with tirzepatide.

The mechanism is accurate too. Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, while semaglutide only targets GLP-1. In the SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022), the highest tirzepatide dose (15mg) produced 20.9% weight loss compared to placebo over 72 weeks.

For context, semaglutide 2.4mg achieved 14.9% weight loss in the STEP 1 trial (Wilding et al., NEJM, 2021). That's a meaningful difference, though both drugs work well.

What's missing from this explanation?

Hasan doesn't mention that we're still learning about GIP's role in weight loss. While the dual mechanism sounds impressive, researchers aren't entirely sure how much the GIP component contributes versus an optimized GLP-1 effect.

He also skips over practical differences. Tirzepatide typically costs more than semaglutide and isn't as widely available. The side effect profiles are similar, but some patients tolerate one better than the other.

The video doesn't address that both medications require lifestyle changes to work optimally. Neither is a magic bullet.

What should you actually know?

Tirzepatide does appear more effective than semaglutide for weight loss, but both are legitimate options. Your choice should depend on factors like insurance coverage, side effects, and availability rather than just efficacy numbers.

Both drugs work by slowing gastric emptying and affecting appetite-regulating hormones. Starting doses are low (2.5mg for tirzepatide, 0.25mg for semaglutide) and increase gradually over months.

The real-world experience matters more than trial results. Some people respond better to one drug over the other for reasons we can't predict. Work with a healthcare provider who understands both options rather than assuming newer automatically means better for your situation.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Dr Zain Hasan · TikTok creator

226.9K views on this video

Full video, save for future reference. #doctor #tirzepatide #semaglutide #glp1forweightloss #doctor

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about tirzepatide achieved 20.9% weight loss in surmount-1 compared to semaglutide's?

Tirzepatide achieved 20.9% weight loss in SURMOUNT-1 compared to semaglutide's 14.9% in STEP 1

What does the video say about tirzepatide targets both glp-1?

Tirzepatide targets both GLP-1 and GIP receptors while semaglutide only affects GLP-1

What does the video say about both medications require gradual dose increases starting from low initial?

Both medications require gradual dose increases starting from low initial doses

What does the video say about head-to-head trials show tirzepatide outperforms semaglutide 1mg in people with?

Head-to-head trials show tirzepatide outperforms semaglutide 1mg in people with diabetes

What does the video say about individual response varies significantly between the two drugs for reasons?

Individual response varies significantly between the two drugs for reasons we can't predict

What does the video say about cost?

Cost and insurance coverage often differ substantially between the medications

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Dr Zain Hasan, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.